Posts tagged Adi Mohanty
BioTime forms new AgeX unit on human aging

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.

Read More
BioTime opens U.S. sites in dry AMD trial

BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S.

Read More
BioTime acquires rights to retinal disease assets

BioTime (NYSE MKT:BTX) has acquired global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center, via the school’s Innovation Institute.

Read More